Category: Wall Street BeatSyndicate content

Standard & Poor's maintains credit watch on Medtronic over Covidien buy

August 22, 2014 by Brad Perriello

Standard & Poor's Ratings Services maintains a credit watch on Medtronic over its $43 billion buyout of Covidien, pending Medtronic's ability to control its indebtedness.

Standard & Poor's puts credit watch on Medtronic over Covidien buy

Covidien snaps up Reverse Medical

August 22, 2014 by Brad Perriello

Covidien snaps up Reverse Medical and its line of vascular devices for an unspecified amount.

YYmeta

Nobel Biocare's Q2 profits double as it fields buyout interest

August 21, 2014 by Brad Perriello

Nobel Biocare doubles its 2nd-quarter profits as it reportedly fields interest – and at least 1 offer worth $2.3 billion – from potential acquirers.

Nobel Biocare's Q2 profits double as it fields buyout interest

Will Medtronic abandon inversion in Covidien deal? | Medtech Wall Street news for the week of August 18, 2014

August 21, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; ElectroCore seeks commercial partners for non-invasive headache tech; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Activist investor battles on over ConMed as shareholders vote approaches; Medtronic's Q1 earnings beat The Street on modest sales bump

Will Medtronic follow Walgreen and abandon inversion in Covidien deal?

August 15, 2014 by Brad Perriello

Report: Allergan solicits Salix in bid to stymie hostile Valeant takeover

August 20, 2014 by Brad Perriello

Allergan reportedly solicits Salix Pharmaceuticals in a bid to stymie the $53 billion hostile takeover move by Valeant Pharmaceuticals and Pershing Square Capital Management.

Report: Allergan solicits Salix in bid to thwart hostile Valeant takeover

Ocular Therapeutix IPO reaches $75M with over-allotment

August 20, 2014 by Arezu Sarvestani

Ocular Therapeutix raises $74.8 million after under-writers grab another 750,000 shares in the company's initial public offering.

Ocular Therapeutix IPO reaches $75M

Bedford, Mass.-based Ocular Therapeutix (NSDQ:OCUL) raised $74.8 million though its initial public offering after underwriters fully exercised an over-allotment option to snag additional shares.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp